| DNA replication |
1.83 |
1.11e-1 |
34/36 (94.44%) |
POLE3;RFC2;PRIM1;...
|
| Neutrophil extracellular trap formation |
1.80 |
7.78e-2 |
101/189 (53.44%) |
CYBB;CTSG;CYBA;...
|
| Progesterone-mediated oocyte maturation |
1.77 |
8.15e-2 |
75/100 (75%) |
KRAS;CCNA2;AKT3;...
|
| Oxytocin signaling pathway |
1.67 |
2.31e-1 |
128/154 (83.12%) |
MYLK;MEF2C;KRAS;...
|
| Nucleotide excision repair |
1.64 |
2.51e-1 |
40/47 (85.11%) |
POLE3;RAD23B;RFC2;...
|
| Oocyte meiosis |
1.64 |
2.09e-1 |
90/129 (69.77%) |
PTTG1;PLK1;PPP2R1A;...
|
| Staphylococcus aureus infection |
1.58 |
2.99e-1 |
72/95 (75.79%) |
DEFB1;KRT10;HLA-DMB;...
|
| Aldosterone-regulated sodium reabsorption |
1.57 |
2.85e-1 |
34/37 (91.89%) |
KRAS;SCNN1A;PRKCB;...
|
| Spliceosome |
1.57 |
2.64e-1 |
101/150 (67.33%) |
PRPF4;LSM7;HSPA2;...
|
| Retinol metabolism |
1.53 |
3.27e-1 |
41/68 (60.29%) |
ALDH1A3;ALDH1A1;ALDH1A2;...
|
| Proximal tubule bicarbonate reclamation |
1.53 |
3.04e-1 |
21/23 (91.3%) |
SLC4A4;CA2;ATP1A1;...
|
| Fc epsilon RI signaling pathway |
1.52 |
3.03e-1 |
57/68 (83.82%) |
FCER1G;KRAS;ALOX5;...
|
| Leukocyte transendothelial migration |
1.50 |
3.24e-1 |
90/114 (78.95%) |
CYBB;CDC42;CYBA;...
|
| Retrograde endocannabinoid signaling |
1.49 |
3.14e-1 |
118/148 (79.73%) |
PRKCB;GABRP;GNG4;...
|
| Oxidative phosphorylation |
1.48 |
3.19e-1 |
93/133 (69.92%) |
ATP5MC2;PPA2;ATP5MC1;...
|
| GABAergic synapse |
1.47 |
3.28e-1 |
76/89 (85.39%) |
SRC;GLUL;PRKCB;...
|
| Fc gamma R-mediated phagocytosis |
1.46 |
3.26e-1 |
79/97 (81.44%) |
MARCKS;PAK1;CDC42;...
|
| Apelin signaling pathway |
1.46 |
3.10e-1 |
117/137 (85.4%) |
MYLK;ACTA2;MEF2C;...
|
| Dopaminergic synapse |
1.46 |
3.05e-1 |
115/132 (87.12%) |
ARRB2;AKT3;PRKCB;...
|
| T cell receptor signaling pathway |
1.46 |
2.92e-1 |
93/104 (89.42%) |
PAK1;CDC42;KRAS;...
|
| Mismatch repair |
1.45 |
2.84e-1 |
22/23 (95.65%) |
RFC2;LIG1;SSBP1;...
|
| VEGF signaling pathway |
1.45 |
2.80e-1 |
50/59 (84.75%) |
CDC42;KRAS;HSPB1;...
|
| C-type lectin receptor signaling pathway |
1.45 |
2.69e-1 |
93/104 (89.42%) |
PAK1;FCER1G;KRAS;...
|
| Tyrosine metabolism |
1.44 |
2.69e-1 |
30/36 (83.33%) |
TYRP1;ALDH3B1;DCT;...
|
| Circadian entrainment |
1.42 |
3.05e-1 |
85/97 (87.63%) |
PER2;PER3;GUCY1B1;...
|
| Glutamatergic synapse |
1.40 |
3.31e-1 |
97/114 (85.09%) |
GLUL;HOMER1;PRKCB;...
|
| Long-term depression |
1.40 |
3.21e-1 |
55/60 (91.67%) |
KRAS;GUCY1B1;PRKCB;...
|
| Diabetic cardiomyopathy |
1.40 |
3.16e-1 |
162/203 (79.8%) |
COL1A2;CYBB;CYBA;...
|
| Steroid biosynthesis |
1.38 |
3.50e-1 |
19/20 (95%) |
CYP51A1;CYP24A1;LSS;...
|
| Phagosome |
1.38 |
3.47e-1 |
118/152 (77.63%) |
CYBB;CYBA;CTSS;...
|
| Cell adhesion molecules |
-1.15 |
5.54e-1 |
118/148 (79.73%) |
SELE;PVR;CADM1;...
|
| Cortisol synthesis and secretion |
-1.16 |
5.55e-1 |
58/65 (89.23%) |
PDE8B;NR0B1;PLCB4;...
|
| Prostate cancer |
-1.21 |
5.24e-1 |
93/97 (95.88%) |
CCNE1;PTEN;IGF1R;...
|
| Linoleic acid metabolism |
-1.22 |
5.28e-1 |
21/29 (72.41%) |
CYP2J2;PLA2G4A;PLA2G2F;...
|
| Caffeine metabolism |
-1.23 |
5.10e-1 |
5/6 (83.33%) |
NAT1;CYP2A6
|
| Hematopoietic cell lineage |
-1.24 |
4.90e-1 |
90/99 (90.91%) |
HLA-DRB1;THPO;CD8A;...
|
| Antigen processing and presentation |
-1.24 |
4.97e-1 |
60/78 (76.92%) |
HLA-F;CTSB;HSP90AB1;...
|
| Gastric cancer |
-1.25 |
5.10e-1 |
122/149 (81.88%) |
CCNE1;FZD2;CSNK1A1;...
|
| Chronic myeloid leukemia |
-1.27 |
4.66e-1 |
72/76 (94.74%) |
SHC1;TGFB2;RUNX1;...
|
| Cytokine-cytokine receptor interaction |
-1.27 |
4.72e-1 |
246/295 (83.39%) |
IL15RA;CD27;TNFSF18;...
|
| Nicotinate and nicotinamide metabolism |
-1.28 |
4.79e-1 |
25/35 (71.43%) |
NMRK2;NADSYN1;QPRT;...
|
| Valine, leucine and isoleucine degradation |
-1.30 |
4.46e-1 |
42/48 (87.5%) |
BCAT2;ACADSB;HADHB;...
|
| Basal transcription factors |
-1.33 |
3.84e-1 |
37/45 (82.22%) |
TBP;GTF2E1;CCNH;...
|
| Glycerophospholipid metabolism |
-1.33 |
4.04e-1 |
71/98 (72.45%) |
LPCAT4;PLA1A;AGPAT4;...
|
| Pathways in cancer |
-1.33 |
4.18e-1 |
474/531 (89.27%) |
IL15RA;DVL2;TRAF3;...
|
| Small cell lung cancer |
-1.35 |
4.04e-1 |
90/92 (97.83%) |
CDKN1B;CCNE2;ITGA6;...
|
| Complement and coagulation cascades |
-1.35 |
4.20e-1 |
76/85 (89.41%) |
CFHR5;C9;TFPI;...
|
| Arginine biosynthesis |
-1.35 |
4.33e-1 |
17/22 (77.27%) |
CPS1;ASS1;ARG2
|
| Steroid hormone biosynthesis |
-1.37 |
4.19e-1 |
43/61 (70.49%) |
AKR1C4;UGT2B4;CYP7A1;...
|
| Regulation of lipolysis in adipocytes |
-1.40 |
3.59e-1 |
52/55 (94.55%) |
TSHR;ADCY1;CGA;...
|
| JAK-STAT signaling pathway |
-1.40 |
3.70e-1 |
146/162 (90.12%) |
IFNA2;STAT3;IFNA5;...
|
| Fatty acid degradation |
-1.40 |
4.00e-1 |
40/43 (93.02%) |
ADH1B;GCDH;ACADSB;...
|
| SNARE interactions in vesicular transport |
-1.40 |
4.36e-1 |
19/33 (57.58%) |
BNIP1;STX6;STX3;...
|
| Malaria |
-1.42 |
4.28e-1 |
44/50 (88%) |
KLRB1;SELE;IL6;...
|
| Aminoacyl-tRNA biosynthesis |
-1.42 |
4.64e-1 |
15/66 (22.73%) |
GATB;WARS2;SARS2;...
|
| Glycerolipid metabolism |
-1.43 |
5.26e-1 |
44/61 (72.13%) |
AKR1B1;LIPF;AGK;...
|
| Central carbon metabolism in cancer |
-1.54 |
3.84e-1 |
67/70 (95.71%) |
TIGAR;SLC7A5;GLS;...
|
| Non-homologous end-joining |
-1.56 |
3.91e-1 |
11/13 (84.62%) |
POLM;NHEJ1;DNTT;...
|
| Ribosome biogenesis in eukaryotes |
-1.60 |
4.19e-1 |
52/108 (48.15%) |
RPP30;IMP3;MDN1;...
|
| Primary immunodeficiency |
-1.69 |
2.68e-1 |
33/38 (86.84%) |
RFX5;AICDA;CD79A;...
|
